Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 75 years old (inclusive) at the time of signing the consent form, both male and female.
• People with locally advanced (stage IIIB or IIIC), metastatic, or recurrent non-small cell lung cancer (a type of lung cancer) confirmed by lab testing, where surgery or combined radiation and chemotherapy as a curative treatment is not an option.
• People who have not previously had systemic (whole-body) treatment for metastatic or recurrent lung cancer; those who had earlier preventive or preparatory treatments (such as chemotherapy or radiotherapy) may still be considered if it has been more than 6 months since that treatment ended and the cancer came back.
• People who can provide a tissue sample for a specific protein test called PD-L1; a recent sample is preferred, but an older stored sample may be accepted if a new one is not available.
• People who have at least one tumour that can be measured using standard imaging criteria (RECIST v1.1).
• People with a general health and activity level rated 0 or 1 on a standard medical scale (meaning fully active or able to carry out light activity).
• People with an expected survival of at least 12 weeks.
• People whose major organ functions (such as liver, kidneys, and blood) meet the levels required by the study protocol.
• Women who could become pregnant, and men whose partners could become pregnant, who are willing to use highly effective contraception during the study and for at least 6 months after the last dose.
• People who are willing to join the study voluntarily, sign a consent form, follow the study requirements, and attend follow-up appointments.

Who may not be able to join:

• People whose lung cancer contains certain other cancer cell types, specifically neuroendocrine components such as small cell lung cancer or large cell neuroendocrine carcinoma, confirmed by lab testing.
• People who have previously received certain treatments specified in the study protocol, including some immune-based therapies and drugs that target a pathway called anti-VEGF (confirm with trial site for the full list).
• People with a significant tendency to bleed or a history of serious blood-clotting problems.
• People who experienced a gastrointestinal perforation (a hole in the gut), an abdominal fistula (an abnormal internal channel), or an abdominal abscess (internal infection) within 6 months before the study starts, or who are currently considered at high risk of these conditions.
• People with a serious unhealed or open wound, an active ulcer, or an untreated bone fracture.
• People with uncontrolled high blood pressure, or a history of a hypertensive crisis or hypertensive encephalopathy (dangerous complications of high blood pressure).
• People whose side effects from previous cancer treatment have not recovered to a mild level (grade 1 or lower on a standard medical scale).
• People with a known allergy to the study drug or its ingredients, to pemetrexed, to platinum-based chemotherapy drugs (carboplatin or cisplatin), or who have had a serious (grade 3 or higher) allergic reaction to any antibody-based medication.

Important: Always verify eligibility with the trial site directly before applying.